UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/554,194	10/24/2005	Yoshio Umezawa	2005_1691A	1885
513 WENDEROTH	7590 07/17/2007	р	EXAM	INER .
WENDEROTH, LIND & PONACK, L.L.P. 2033 K STREET N. W.			CHEN, SHIN LIN	
SUITE 800 WASHINGTON, DC 20006-1021			ART UNIT	PAPER NUMBER
		· ·	1632	
		·	MAIL DATE	DELIVERY MODE
			07/17/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)	
	10/554,194	UMEZAWA ET AL.	
Office Action Summary	Examiner	Art Unit	
	Shin-Lin Chen	1632	
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address	
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	. the mailing date of this communication. (35 U.S.C. § 133).	
Status	·		
1) Responsive to communication(s) filed on 2a) This action is FINAL . 2b) This 3) Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro		
Disposition of Claims			
 4) Claim(s) 1-14 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-14 are subject to restriction and/or expressions. 	·		
Application Papers			
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the of Replacement drawing sheet(s) including the correction 11) The oath or declaration is objected to by the Examiner 9) The specification is objected to by the Examiner 10) The specification is objected to by the Examiner 11) The oath or declaration is objected to by the Examiner 11)	epted or b) objected to by the Edrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).	
Priority under 35 U.S.C. § 119		•	
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No ed in this National Stage	
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa	ite	

Application/Control Number: 10/554,194

Art Unit: 1632

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-7, drawn to a probe for detection and quantification of a lipid second messenger, which comprises a lipid second messenger-binding protein, such as a pleckstrin homology domain, two chromophores having different fluorescence wavelengths, and a membrane localization sequence linked to one of the chromophores through a linker sequence.

Group II, claim(s) 8, drawn to a method for detecting and quantifying a lipid second messenger with co-existing probe and the lipid second messenger.

Group III, claim(s) 9 and 11, drawn to a method for detecting an quantifying a lipid second messenger by introducing a polynucleotide expressing the probe into cells.

Group IV, claim(s) 10 and 14, drawn to a method for detecting and quantifying a lipid second messenger by introducing a polynucleotide expressing the probe into a non-human totipotent cell and ontogenizing the cell to non-human animal.

Group V, claim(s) 12, drawn to a non-human animal or offspring animal thereof obtained by introducing a polynucleotide expressing the probe into a non-human totipotent cell and ontogenizing the cell to non-human animal.

Group VI, claim(s) 13, drawn to a method for screening a substance for quantifying a lipid second messenger by introducing a test sample into the non-human animal or the offspring animal thereof.

2. The inventions listed as Groups I-VI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The special technical feature common to groups I-VI is the probe comprising a lipid second messenger-binding protein, such as a pleckstrin homology domain, two chromophores having different fluorescence wavelengths, and a membrane localization sequence linked to one of the chromophores through a linker sequence. Jalink, K., 2002 (WO 02/44720 A2) discloses a membrane molecule indicator comprising at least one membrane molecule indicator domain, such as a pleckstrin homology (PH) domain, a donor fluorescent domain and an acceptor fluorescent domain, wherein fluorescence resonance energy transfer (FRET) between said donor domain and said acceptor domain is indicative of a property of said membrane molecule. The indicator can further comprise a membrane anchoring domain,

Application/Control Number: 10/554,194

Art Unit: 1632

such as a CaaX motif. The donor fluorescent domain could be a CFP and the acceptor fluorescent domain could be a YFP. The membrane molecule could be a lipid, such as PIP2 (e.g. p. 71-72, Figure 2A-2C). The membrane anchoring domain is considered a membrane localization sequence. Jalink further discloses nucleic acid molecule encoding the membrane molecule indicator (e.g. p. 73-75). Therefore, no special technical feature has been contributed over the prior art by the instant invention. Further, the probe and the non-human animal do not share core structures or common properties. Thus, Groups I-VI do not relate to a single general inventive concept under PCT Rule 13.1.

3. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 10/554,194

Art Unit: 1632

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shin-Lin Chen whose telephone number is (571) 272-0726. The examiner can normally be reached on Monday to Friday from 9:30 am to 6 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Peter Paras can be reached on (571) 272-4517. The fax phone number for this group is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Shin-Lin Chen, Ph.D.

SHIN-LIN CHEN PRIMARY EXAMINER

4Mhon